Axxam S.p.A. Company Profile

Background

Overview

Axxam S.p.A. is an innovative Partner Research Organization (iPRO) specializing in early-stage drug discovery services across the life sciences sector. Established in 2001, the company is headquartered at the OpenZone Campus in Bresso, near Milan, Italy. Axxam offers integrated services encompassing target validation, assay development, high-throughput screening, hit identification, and lead optimization. The company also identifies new bioactive compounds for crop protection, animal health, food and beverage, pet food, cosmetics, and perfume industries.

Mission and Vision

Axxam's mission is to support clients and partners in transforming ideas into actionable discoveries by translating innovative biology into bioactive molecules. The company strives to push the boundaries of science to solve complex challenges and make a meaningful difference in people's lives, aiming to lead the way in life sciences and create solutions that inspire a healthier, more sustainable world.

Industry Significance

As a Contract Research Organization (CRO), Axxam plays a pivotal role in the early stages of drug discovery, providing essential services that accelerate the development of new therapeutics. Its expertise spans various disciplines, including assay development, high-throughput screening, and hit-to-lead optimization, making it a valuable partner for pharmaceutical and biotechnology companies worldwide.

Key Strategic Focus

Core Objectives

Axxam focuses on delivering high-quality, customized solutions to support clients in generating valuable leads across multiple therapeutic areas and target classes. The company's services are designed to address the unique challenges of early-stage drug discovery, from target assessment and hit identification to lead generation.

Areas of Specialization

Assay Development: Designing and developing advanced cell-free and cell-based in vitro assays.

High-Throughput Screening (HTS): Conducting high-throughput screening campaigns using proprietary synthetic and natural compound collections or client-provided libraries.

Hit-to-Lead Optimization: Advancing promising leads to the next phases of development.

Key Technologies Utilized

Axxam integrates state-of-the-art advancements, including artificial intelligence and machine learning, into its work. The company employs various advanced detection technologies, such as optical readouts (luminescence/fluorescence), electrophysiology, high-content screening, and quantitative gene expression, to test both in-house and client-provided compound collections.

Primary Markets Targeted

Axxam serves a diverse clientele, including pharmaceutical and biotechnology companies, start-ups, patient foundations, and academic groups. The company also applies its science-driven approach to identify new bioactive compounds for crop protection, animal health, food and beverage, pet food, cosmetics, and perfume industries.

Financials and Funding

Funding History

In July 2022, Keensight Capital, a leading European private equity firm, acquired a majority stake in Axxam. This investment was intended to support the management team in pursuing and accelerating the company's growth, realizing its significant potential.

Recent Funding Rounds

The acquisition by Keensight Capital in 2022 marked a significant development in Axxam's funding history. Prior to this, the company had received support from Bayer SpA and Zambon Company SpA.

Notable Investors

Keensight Capital: Acquired a majority stake in Axxam in July 2022.

Bayer SpA: Previous shareholder.

Zambon Company SpA: Previous shareholder.

Utilization of Capital

The investment from Keensight Capital is intended to support Axxam's growth initiatives, including expanding its service offerings, enhancing technological capabilities, and strengthening its position in the global market.

Pipeline Development

Axxam's pipeline development focuses on early-stage drug discovery, providing services that support the identification and validation of bioactive molecules across various therapeutic areas. The company's expertise spans target assessment, assay development, high-throughput screening, hit identification, and lead optimization. Axxam also identifies new bioactive compounds for crop protection, animal health, food and beverage, pet food, cosmetics, and perfume industries.

Technological Platform and Innovation

Proprietary Technologies

Organellar Electrophysiology Platform: A pioneering platform developed by Axxam for advanced electrophysiological studies.

iPSC-Derived Models: Utilizing induced pluripotent stem cell-derived models for drug discovery.

Optogenetics: Incorporating optogenetic techniques into research methodologies.

High-Content Screening: Employing high-content screening technologies for comprehensive analysis.

Significant Scientific Methods

Assays: Development of advanced cell-free and cell-based in vitro assays.

Machine Learning Algorithms: Integration of artificial intelligence and machine learning for target identification and compound library design.

AI-Driven Capabilities

Axxam embraces transformative advancements like artificial intelligence to remain at the forefront of scientific innovation, integrating AI-driven capabilities into its discovery processes.

Leadership Team

Key Executives

Dr. Stefan Lohmer: Co-founder and CEO of Axxam.

Dr. Alessandro Sidoli: Co-founder and CEO of Axxam.

Ciriaco Maraschiello: Chief Operating Officer (COO) of Axxam.

Luigi Gavazzeni: Chief Financial Officer (CFO) of Axxam.

Professional Backgrounds and Contributions

Dr. Stefan Lohmer: Co-founder and CEO, leading Axxam's strategic direction and growth initiatives.

Dr. Alessandro Sidoli: Co-founder and CEO, overseeing Axxam's operations and scientific advancements.

Ciriaco Maraschiello: COO, responsible for operational management and client engagement.

Luigi Gavazzeni: CFO, managing financial strategies and investments.

Recent Leadership Changes

In July 2022, Keensight Capital acquired a majority stake in Axxam, leading to strategic growth initiatives and potential leadership developments.

Competitor Profile

Market Insights and Dynamics

The contract research organization (CRO) market, particularly in early-stage drug discovery, is characterized by rapid technological advancements and increasing demand for specialized services. Companies like Axxam are positioned to capitalize on these trends by offering integrated and innovative solutions.

Competitor Analysis

Symeres: A leading European CRO offering integrated drug discovery services from hit to clinic.

leadXpro: Specializes in structure-based drug discovery for membrane protein targets.

MercachemSyncom: Provides innovative chemistry and medicinal chemistry services to accelerate drug discovery.

Strategic Collaborations and Partnerships

Axxam has formed several strategic alliances to enhance its service offerings:

Momentum Biotechnologies: In November 2023, Axxam and Momentum Biotechnologies announced a partnership to provide unique drug discovery solutions, integrating Axxam's chemical diversity library with Momentum's mass spectrometry-based platforms.

Isogenica Ltd.: In September 2024, Axxam and Isogenica Ltd. announced a collaboration to offer unique VHH antibody discovery solutions, combining Axxam's assay development capabilities with Isogenica's antibody discovery expertise.

Fujifilm Cellular Dynamics Inc.: In October 2020, Axxam and Fujifilm Cellular Dynamics entered an alliance to improve the drug discovery process by providing access to an integrated platform of hiPSC-based assays.

Operational Insights

Axxam's strategic collaborations enhance its capabilities in early drug discovery, allowing the company to offer comprehensive and innovative solutions to its clients. These partnerships strengthen Axxam's position in the competitive landscape by integrating diverse expertise and technologies.